Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:CBAINYSE:EVGNYSE:GBSNASDAQ:PBLANASDAQ:SQL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAICBA Florida$0.01+1.3%$0.01$0.01▼$0.01$9.91MN/A2.73 million shs19.77 million shsEVGEaton Vance Short Duration Diversified Income Fund$10.36-0.8%$10.59$9.13▼$10.86N/AN/A48,189 shs45,131 shsGBSGBS$2.57-7.6%$4.10$0.36▼$2.89$38.27M1.32955,325 shs51,711 shsPBLAPanbela Therapeutics$0.44+7.3%$0.77$0.40▼$477.00$1.53M1.48573,537 shs25,779 shsSQLSeqLL$4.16$6.50▼$96.00$2.52M1.3452,119 shs22,000 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAICBA Florida0.00%0.00%0.00%0.00%0.00%EVGEaton Vance Short Duration Diversified Income Fund-0.71%+0.63%-0.43%-0.71%+5.94%GBSGBS0.00%-5.44%-28.17%+1,135.01%+6.92%PBLAPanbela Therapeutics-2.36%-20.52%-35.92%-87.38%-99.84%SQLSeqLL0.00%0.00%0.00%+71.32%-64.59%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAICBA FloridaN/AN/AN/AN/AN/AN/AN/AN/AEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AN/AN/AN/AN/AN/AGBSGBSN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.6899 of 5 stars3.50.00.00.00.00.00.6SQLSeqLLN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAICBA FloridaN/AN/AN/AN/AEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AN/AGBSGBSN/AN/AN/AN/APBLAPanbela Therapeutics3.00Buy$500.00113,536.36% UpsideSQLSeqLLN/AN/AN/AN/ACurrent Analyst RatingsLatest GBS, CBAI, SQL, PBLA, and EVG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAICBA FloridaN/AN/AN/AN/AN/AN/AEVGEaton Vance Short Duration Diversified Income Fund$13.79MN/AN/AN/AN/AN/AGBSGBS$440K86.97N/AN/A$0.44 per share5.84PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ASQLSeqLL$80K0.00N/AN/A$14.70 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAICBA Florida-$40KN/A0.00∞N/AN/AN/AN/AN/AEVGEaton Vance Short Duration Diversified Income FundN/AN/A0.00∞N/AN/AN/AN/AN/AGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/APBLAPanbela Therapeutics-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%5/2/2024 (Estimated)SQLSeqLL-$4.09M-$16.40N/AN/AN/AN/A-124.09%-64.18%N/ALatest GBS, CBAI, SQL, PBLA, and EVG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAICBA FloridaN/AN/AN/AN/AN/AEVGEaton Vance Short Duration Diversified Income Fund$0.928.88%+8.62%N/A1 YearsGBSGBSN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ASQLSeqLLN/AN/AN/AN/AN/ALatest GBS, CBAI, SQL, PBLA, and EVG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/1/2024EVGEaton Vance Short Duration Diversified Income FundMonthly$0.07909.01%4/22/20244/23/20244/30/20243/1/2024EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07868.6%3/20/20243/21/20243/28/20242/1/2024EVGEaton Vance Short Duration Diversified Income Fundmonthly$0.07878.7%2/21/20242/22/20242/29/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAICBA FloridaN/AN/AN/AEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/AGBSGBSN/A2.332.33PBLAPanbela TherapeuticsN/A0.250.25SQLSeqLL0.505.045.04OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAICBA FloridaN/AEVGEaton Vance Short Duration Diversified Income FundN/AGBSGBS2.79%PBLAPanbela Therapeutics4.37%SQLSeqLL1.82%Insider OwnershipCompanyInsider OwnershipCBAICBA Florida30.00%EVGEaton Vance Short Duration Diversified Income FundN/AGBSGBS0.27%PBLAPanbela Therapeutics0.01%SQLSeqLL22.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBAICBA Florida21.27 billion890.45 millionNot OptionableEVGEaton Vance Short Duration Diversified Income FundN/AN/AN/ANot OptionableGBSGBS714.89 million14.85 millionNot OptionablePBLAPanbela Therapeutics63.48 million3.48 millionNot OptionableSQLSeqLL7381,000296,000Not OptionableGBS, CBAI, SQL, PBLA, and EVG HeadlinesSourceHeadlineSeqLL (NASDAQ:SQL) Shares Down 20.2% americanbankingnews.com - April 16 at 2:12 AMSeqLL Inc. (SEQL) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 19 at 2:42 PMSeqLL defers proposed cash and stock distributions in connection with proposed acquisitionmsn.com - October 30 at 7:02 PMSeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisitionfinance.yahoo.com - October 30 at 7:01 PMSeqLL Announces Cash and Stock Dividend Record Datefinance.yahoo.com - September 15 at 8:12 PMSeqLL Shares Jump on 1-for-40 Reverse Stock Split Planmarketwatch.com - August 31 at 6:56 PMSeqll Inc.: SeqLL to Conduct 1-for-40 Reverse Stock Splitfinanznachrichten.de - August 31 at 8:00 AMSeqLL to effect 1-for-40 reverse stock splitmsn.com - August 30 at 4:58 PMSeqLL to Conduct 1-for-40 Reverse Stock Splitfinance.yahoo.com - August 30 at 4:58 PMPotential Price Increase for SeqLL Inc. (SQL) After Recent Insider Activityknoxdaily.com - June 19 at 12:10 PMInvesting in SeqLL Inc. (SQL) Is Getting More Attractiveknoxdaily.com - June 5 at 10:52 AMSeqLL Stock (NASDAQ:SQL), Insider Trading Activitybenzinga.com - June 1 at 12:40 PM0 analysts rank SQL stock as an Overweightknoxdaily.com - June 1 at 12:40 PMSeqLL Inc. Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition Corp.finance.yahoo.com - May 30 at 9:35 AMWhy Is SeqLL (SQL) Stock Up 43% Today?investorplace.com - May 22 at 9:10 AMSeqll Inc.: SeqLL Provides First Quarter 2023 Financial Resultsfinanznachrichten.de - May 9 at 5:10 PMSeqLL Provides First Quarter 2023 Financial Resultsfinance.yahoo.com - May 9 at 8:37 AMSeqll Inc.: SeqLL Announces Fourth Quarter and Year End 2022 Financial Resultsfinanznachrichten.de - March 17 at 2:00 PMSeqLL Announces Fourth Quarter and Year End 2022 Financial Resultsfinance.yahoo.com - March 17 at 8:59 AMSeqLL Stock (NASDAQ:SQL), Short Interest Reportbenzinga.com - March 2 at 5:31 PMVolatile SQL Stock Could Give Risk-Tolerant Investors a Wild Rideinvestorplace.com - February 22 at 6:19 AMSeqLL Inc. Announces Closing of $1.8 Million Registered Direct Offeringfinance.yahoo.com - February 15 at 5:32 PMSeqLL Shares Drop 16% After Direct Offering Pricesmarketwatch.com - February 13 at 1:21 PMSeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offeringfinance.yahoo.com - February 13 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCBA FloridaOTCMKTS:CBAICBA Florida, Inc. does not have significant operations. Previously, the company provided private cord blood and cord tissue stem cell services. The company was formerly known as Cord Blood America, Inc. and changed its name to CBA Florida, Inc. in May 2018. CBA Florida, Inc. is based in Las Vegas, Nevada.Eaton Vance Short Duration Diversified Income FundNYSE:EVGEaton Vance Short Duration Diversified Income Fund is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. The fund invests in fixed income markets of the United States. It primarily invests in senior, secured floating-rate loans, bank deposits denominated in foreign currencies, debt obligations of foreign governmental and corporate issuers, and mortgage-backed securities. The fund invests in fixed income securities operating across diversified sectors. It invests in fixed income securities with an average duration of 1.76 years and an average credit quality of least BBB. The fund benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. It was formerly known as Eaton Vance Low Duration Diversified Income Fund. Eaton Vance Short Duration Diversified Income Fund was formed on February 28, 2005 and is domiciled in the United States.GBSNYSE:GBSGBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.SeqLLNASDAQ:SQLSeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.